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Prescription of hormone replacement therapy in postmeno- In the general population, the benefits of hormone
pausal women with renal failure. replacement therapy (HRT) have been confirmed in
Background. Although patients with end-stage renal disease many clinical trials and include the relief of menopausal
(ESRD) are at increased risk for early menopause, osteoporo- symptoms, the maintenance of bone mass, reduction insis, cognitive dysfunction, and cardiovascular disease, few post-
the risk for osteoporosis, improvement in cognitive func-menopausal women are prescribed hormone replacement ther-
tion, and improvement of the lipid profile [1–5]. In addi-apy (HRT). The reasons for the low prescription rate are not
known. This study uses data from the United States Renal tion, results of observational and cross-sectional studies
Data System (USRDS) to assess the prevalence and predictors of HRT have suggested that HRT may reduce the risk
of HRT use in postmenopausal women with ESRD. for cardiovascular disease by as much as 35 to 42% and
Methods. Data were obtained from the USRDS Dialysis may prevent the development of dementia [4, 6, 7].
Morbidity and Mortality Study Wave 2. All women who were
As a result of these studies, the use of HRT in theat least 45 years of age were considered postmenopausal and
general population has been increasing over the past 20were selected for our analysis. Demographics, behavior and
years [8]. Between 1982 and 1992, the number of HRTmedical characteristics were abstracted from the database. Lo-
gistic regression was used to estimate the independent contri- prescriptions dispensed increased from 13.2 to 36 million
bution of population characteristics in predicting the use of [8]. In the United States, 34% of postmenopausal women
HRT. Linear regression models were used to estimate the are prescribed HRT, but the prevalence varies consider-
relationship between HRT use and both triglycerides and total ably by a variety of factors, including patient and physi-cholesterol.
cian attitude, geographic location, and ethnicity [9].Results. The overall prevalence of HRT prescription was
Although patients with end-stage renal disease (ESRD)10.8%. Important predictors of HRT use included age (aOR 5
are at increased risk for early menopause, cardiovascular0.74, 95% CI 0.13 to 0.88, P , 0.001), black ethnicity (aOR 5
0.50, 95% CI, 0.31 to 0.78, P , 0.002), college education disease, osteoporosis, and cognitive dysfunction [10–13],
(aOR 5 3.00, 95% CI, 1.70 to 5.24, P , 0.001), and the ability only 10% of postmenopausal women are prescribed HRT
to ambulate (aOR 5 1.99, 95% CI, 1.01 to 3.91, P 5 0.05). [14]. The reasons for the low prescription rate among
Serum triglyceride and total cholesterol levels were higher
ESRD patients are not known. Recognition of factorsamong women treated with HRT than among those not treated
important in predicting the prescription of HRT may helpwith HRT (264 6 155 vs. 217 6 159 mg/dl, P 5 0.001 and 220 6
physicians target populations of patients who are pre-62 vs. 209 6 55 mg/dl, P 5 0.02, respectively).
Conclusions. HRT is prescribed less frequently in post- scribed HRT less frequently but who may benefit from
menopausal ESRD patients than in the general population. HRT. This study uses data from the United States Renal
Younger age, higher education levels, white race, and the abil- Data System (USRDS) to assess the prevalence and pre-
ity to ambulate were important predictors of HRT use. Tar- dictors of HRT use in postmenopausal women with ESRD.
geting populations of patients who are likely to benefit from
but less likely to be prescribed HRT may increase the prescrip-
tion of HRT. METHODS
Patient population
We performed a secondary analysis of data from theKey words: ESRD, women, hormone prescription, menopause, cardio-
vascular disease. USRDS Dialysis Morbidity and Mortality Study (DMMS)
Wave 2. Details of the design of the DMMS Wave 2Received for publication April 1, 1999
study are described in more detail elsewhere [15]. Briefly,and in revised form June 9, 1999
Accepted for publication August 3, 1998 the USRDS collects demographic and clinical data on
patients who have survived more than 90 days on dialysis 1999 by the International Society of Nephrology
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Table 1. Selected characteristics of the patient populationand who qualify for Medicare. DMMS Wave 2 was a
prospective study that included a random sample of inci- Hormone No hormone
replacement replacementdent dialysis patients in 1996 who were sampled from
therapy therapyamong 25% of the dialysis units listed in the December N 5 162 N 5 1337
1993 Master List in addition to all new dialysis units
N (%)
opening after January 1, 1994. The USRDS excluded
Agepatients from DMMS Wave 2 if they were younger than
45 to 59 years 86 (53%) 417 (31%)
18 years or were home dialysis patients or if they had 60 to 74 years 62 (38%) 690 (52%)
.75 years 14 (9%) 230 (17%)been previously transplanted. Modality assignment was
Racedetermined on day 60 of ESRD. All women who were
White 123 (76%) 817 (62%)
at least 45 years of age were considered postmenopausal Black 29 (18%) 400 (30%)
Other 10 (6%) 108 (8%)and were selected for our analysis.
Education
Some high school 29 (20%) 493 (41%)Data collection
High school graduate 56 (39%) 421 (35%)
Some college 29 (20%) 152 (13%)Dialysis facility personnel abstracted data for patients
College graduate 30 (21%) 129 (11%)from their dialysis record. A maximum of 15 medications
Diabetes 74 (47%) 760 (58%)
prescribed to each study patient at the study start date Coronary artery disease 42 (28%) 464 (38%)
Uterine Cancer 3 (2%) 18 (1%)(day 60) were recorded. From this list, the use of estrogen,
Breast Cancer 3 (2%) 41 (3%)progesterone, or combination preparations was deter-
Obesity 71 (46%) 674 (52%)
mined. Patients were categorized as having been pre- Exercise frequency
Frequently 22 (22%) 168 (21%)scribed HRT if an estrogen, progesterone, or a combina-
Occasionally 27 (27%) 198 (25%)tion preparation was found on their list of medications.
Never 52 (52%) 419 (53%)
Demographics and behavioral characteristics ascertained Smoker
Active 3 (3%) 21 (2%)included age, race (white, black, other), gender, dialysis
Former 22 (19%) 204 (19%)modality [hemodialysis (HD) or peritoneal dialysis (PD)],
Never 89 (78%) 846 (79%)
education (less than 12 years, high school graduate, some Treatment modality
Peritoneal dialysis 100 (62%) 568 (43%)college, college graduate), employment status (employed,
Hemodialysis 62 (38%) 766 (57%)not employed), exercise (frequently, occasionally, never),
the process of choosing the initial treatment for kidney
failure (patient took the lead, medical team took the
lead, medical team and patient jointly took the lead),
difference in either triglycerides or total cholesterol be-marital status (married, not married), and tobacco use
tween women who take HRT and those that do not,(active, former, never). The medical history ascertained
along with 95% confidence intervals. Data were analyzedincluded coronary artery disease (yes, no), peripheral
with SPSS statistical software (SPSS, Chicago, IL, USA).vascular disease (yes, no), diabetes (yes, no), history of
breast cancer (yes, no), history of uterine cancer (yes,
no), total cholesterol, and triglycerides. The body mass RESULTS
index was calculated from height and weight, and obesity
Prescription of HRT was assessed in 1499 women. Thewas defined as a body mass index $25.
characteristics of the patient population are summarized
in Table 1. Patients prescribed HRT tended to be younger,Statistical analysis
white, more educated, and treated with PD, and theyLogistic regression was used to estimate the indepen-
were less likely to have diabetes or heart disease. Patientsdent contribution of demographic, behavioral and medi-
prescribed HRT were similar to patients not prescribedcal history variables in predicting the use of HRT in
HRT with regard to history of uterine and breast cancer,postmenopausal women with ESRD. The continuous
frequency of obesity, exercise frequency, and use of to-variables of interest were analyzed separately in categori-
bacco.cal form for ease of interpretation. In the final model,
The overall prevalence of HRT prescription amongthe odds ratios are interpretable as the adjusted odds
postmenopausal women with ESRD was 10.8% (162 outof being prescribed HRT for each variable of interest,
of 1499). The prevalence of prescription was 15% in theholding all other factors constant. The estimated stan-
forth decade of life, 18% in the fifth decade of life, 8%dard error of the coefficient (B1) from the logistic regres-
in the sixth decade of life, 8% in the seventh decade ofsion analysis was used to establish confidence intervals.
life, and 7% in the eighth decade of life. Twenty womenLinear regression models were used to estimate the rela-
less than 45 years of age were also taking HRT but weretionship between HRT use and both triglycerides and
total cholesterol. Results were reported as the mean not included in the analysis. Five percent (N 5 8) of
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Table 2. Odds of being prescribed hormone replacement therapy among postmenopausal women with end-stage renal disease
Covariate OR (95% CI) P value aOR (95%CI)a P value
Age (decades) 0.67 (0.57, 0.78) ,0.001 0.74 (0.13, 0.88) ,0.001
45–59 years 1 1
60–74 years 0.44 (0.31, 0.62) ,0.001 0.49 (0.36, 0.72) ,0.001
.75 years 0.30 (0.16, 0.53) ,0.001 0.38 (0.20, 0.73) 0.003
Education
Some high school 1 1
High school graduate 2.26 (1.42, 3.60) ,0.001 1.83 (1.13, 2.95) 0.01
Some college 3.24 (1.88, 5.59) ,0.001 2.44 (1.39, 4.29) 0.002
College graduate 3.95 (2.29, 6.82) ,0.001 2.98 (1.70, 5.24) ,0.001
Race 0.002 0.009
White 1 1
Black 0.48 (0.32, 0.73) ,0.001 0.50 (0.31, 0.78) 0.002
Other 0.61 (0.31, 1.21) 0.16 0.69 (0.33, 1.45) 0.33
Independent ambulation 2.86 (1.53, 5.37) 0.001 1.99 (1.01, 3.91) 0.05
Abbreviations are: OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio.
a Adjusted for age, education, race, and independent ambulation
women were prescribed a combination preparation, Triglyceride levels in women prescribed HRT were
47.2 mg/dl (95% CI, 18.9 to 75.5) points higher on aver-whereas the remaining (N 5 154) were prescribed estro-
gen and/or progesterone as separate prescriptions. age than in women not prescribed HRT (264 6 155 vs.
217 6 159 mg/dl, P 5 0.001). Cholesterol levels wereImportant predictors of HRT prescription are summa-
rized in Table 2. For every decade of life, patients were 11.0 mg/dl (95% CI, 1.5 to 20.5) higher on average among
women prescribed HRT compared with women not pre-26% less likely to be prescribed HRT after adjusting for
education, race, and independent ambulation (aOR 5 scribed HRT (220 6 62 vs. 209 6 55 mg/dl, P 5 0.02).
0.74, 95% CI, 0.13 to 0.88, P , 0.001). Patients who were
more educated were more likely to be prescribed HRT
DISCUSSION
after adjusting for age, race, and independent ambula-
We estimated the prevalence of HRT use amongtion. Patients who were college graduates were threefold
women with ESRD to be 10.8%. Important predictorsmore likely to be prescribed HRT than those with less
of HRT use among women with ESRD included youngerthan a high school education (aOR 5 2.98, 95% CI, 1.70
age, higher education levels, white race, and the abilityto 5.24, P , 0.001). Black patients were 50% less likely
to ambulate. Serum triglyceride and cholesterol levelsto be prescribed HRT than white patients (aOR 5 0.50,
were higher among women with ESRD prescribed HRT95% CI, 0.31 to 0.78, P , 0.002) after adjusting for age,
than among those not prescribed HRT.education, and independent ambulation. Women who
We found that HRT is used with less frequency inwere able to ambulate were almost twofold more likely
postmenopausal ESRD patients (10.8%) than in the gen-to be prescribed HRT than patients who were not able
eral population. Investigators from The Commonwealthto ambulate after adjusting for age, education, and race
Fund 1998 Survey of Women’s Health estimated the(aOR 5 1.99, 95% CI, 1.01 to 3.91, P 5 0.05).
prevalence of HRT use in the United States amongDiabetic women were less likely to be prescribed HRT
women $50 years of age to be 34%. They surveyed morethan nondiabetic women (OR 5 0.65, 95% CI, 0.47 to
than 2000 women over the age of 18 years, weighting0.91, P 5 0.01). Women treated with PD were more than
results with census data by age, sex, race, education,twofold more likely to be prescribed HRT than women
insurance, and geographic region to produce results rep-treated with HD (OR 5 2.17, 95% CI, 1.56 to 3.04, P ,
resentative of women in the United States. The preva-0.001). Women who shared in choosing treatment op-
lence of HRT use has been reported to be as high astions with their medical team were 1.78-fold more likely
47% among a cohort of women physicians in the Unitedto be prescribed HRT than women who let the medical
States [16] and as low as 9.3% among a population ofteam make the decision (OR 5 1.78, 95% CI, 1.11 to
middle-aged white women from Massachusetts [17]. Dif-2.84, P , 0.01). However, these associations were no
ferences in the prescription of HRT have been explainedlonger statistically significant after adjusting for age, edu-
by a variety of factors including physician attitude, secu-cation, race, and independent ambulation and were not
lar trends, geographic location, and ethnicity [8, 17–19].included in the final model. History of breast and uterine
Variation in the demographic distribution betweencancer, body mass index, exercise frequency, employ-
women with and without ESRD may account for muchment status, marital status, and tobacco use were not
of the differences in prescription rate.important in predicting HRT and therefore were not
included in the final model. Among postmenopausal ESRD patients, younger age,
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higher education levels, white race, and the ability to cardiovascular disease, bone disease, cognitive function
and venous thrombosis in women with ESRD.ambulate were the most important predictors of HRT
The analysis has certain limitations. Although we wereprescription. The results of this study are consistent with
able to determine the type of hormone preparation, weprevious studies describing HRT use in women without
were unable to determine if women had previously beenESRD [19–21]. It is possible that patients with higher
prescribed HRT, the duration of HRT use, or the reasonseducation levels are more likely to consider the potential
for discontinuation of HRT. It is possible that factorsbenefits of HRT and discuss its use with their physician.
such as dysfunctional uterine bleeding associated withAmbulatory women with ESRD were more likely to be
HRT in the setting of heparin use may be an importantprescribed HRT. Patients who are bedridden may have
predictor of HRT use, which we were unable to quanti-more severe medical problems. Physicians may consider
tate. In addition, because there were a limited number ofHRT not efficacious in this population of women who
spaces available to enter medications, HRT prescriptionare at such high risk for death. It is not known whether
may have been underestimated. Second, women whothis is a reasonable assumption. The declining use of
were home HD patients or who had been previouslyHRT with advancing age has been noted among patients
transplanted were excluded in the original data collectionwithout ESRD and was observed in this study. Postulated
for DMMS Wave 2 by the USRDS. This may have re-reasons include fear of breast cancer with long-term use
sulted in the selection of a less healthy study population.of HRT and side-effects of the medication [22, 23]. The
If women who are healthier are more likely to be pre-lower prescription of HRT among black compared to
scribed HRT, this may have underestimated the preva-white women has also been described [24]. Physicians
lence of HRT use among women with ESRD. However,may be less inclined to prescribe HRT to black women
the USRDS collected data for Wave 2 on incident (new)who are at lower risk for osteoporosis. Alternatively,
dialysis patients. A minority of patients are transplantedrace may be a marker for socioeconomic status, which
prior to the initiation of dialysis. In addition, home HDhas been shown to be predictive of HRT use.
represents a very small number of patients (1.1%).In contrast to studies of women without ESRD, we did
Therefore, it is unlikely that many patients were ineligi-not find that body mass index, previous hysterectomy,
ble secondary to previous transplant or home HD. Fi-or history of uterine or breast cancer were important
nally, although we defined menopause as an age of $45predictors of HRT [16, 19, 25]. The lack of association
years, there are very little data regarding the averagebetween breast or uterine cancer and prescription of
age of menopause in women with ESRD. Menopause isHRT may be the result of the relatively rare occurrence
thought to occur earlier among women with ESRD. Aof these cancers in the study population. Alternatively,
study by Holley et al reported that the median age of
there may have been underreporting of previous neo-
menopause was 47 years and ranged from 40 to 53 years
plasms in the survey. [14]. Thus, $45 was chosen as a reasonable age to include
Although estrogen has many beneficial effects, it is most women who were postmenopausal. In addition,
also associated with an increase in serum triglycerides although we may have included some women in their
[5]. Our data demonstrated higher triglycerides among 40s who were premenopausal, the overall prevalence of
patients treated with HRT compared with those not HRT use did not change significantly if $45 years or
treated. We also found that total cholesterol levels in $50 years was used to define menopause (10.8 vs. 10.3%,
women prescribed HRT were higher than in those not respectively). Although there are number of acknowl-
prescribed HRT. It may be that women with higher cho- edged limitations, this study is the first to report the
lesterol and/or triglyceride levels are more likely to be pattern of use of HRT in the dialysis population and the
prescribed HRT. If this were the case, despite HRT, first to describe factors important in its prescription.
total cholesterol may remain higher in those treated than The prescription of HRT is lower in postmenopausal
in those not treated. Given the cross-sectional design of women with ESRD than in the general population.
this study, a causal relationship between HRT and serum Among women with ESRD, younger age, higher educa-
lipids can not be assessed. tion levels, white race, and the ability to ambulate were
There are many reasons why women with ESRD may the most important predictors of prescription of HRT.
receive particular benefit from HRT therapy. Among Targeting these groups of women with ESRD who are
patients without ESRD, HRT is effective in improving likely to benefit from but less likely to be prescribed
the lipid profile, stabilizing bone mass, reducing fracture HRT may increase the prescription of HRT. Further
rate [1, 3], and improving cognitive function [4]. If the studies need to identify factors that account for differ-
benefits are similar among ESRD patients to the general ences in prescription rate between women with and with-
population, increasing the prescription of HRT could out renal disease and address the impact of HRT on
improve morbidity and mortality in women with ESRD. cardiovascular disease, bone loss, cognitive function and
venous thrombosis.Further studies need to address the impact of HRT on
Stehman-Breen et al: HRT and renal failure 2247
vascular characteristics of long-term end-stage renal disease survi-ACKNOWLEDGMENTS
vors. Am J Kidney Dis 28:931–936, 1996
11. Stein M, Packham D, Ebeling P, Ward J, Becker G: PrevalenceThis study was supported by a Veterans Administration Career
Development Award. We would like to thank Dr. Donald Sherrard and risk factors for osteopenia in dialysis patients. Am J Kidney
Dis 28:515–522, 1996for reviewing the manuscript. The data reported here have been sup-
plied by the USRDS. The interpretation and reporting of these data 12. Erlichman M, Holohan T: Bone densitometry: Patients with end
stage renal disease. Health Technol Assess 8:1–27, 1996are the responsibility of the authors, and in no way should be seen as
an official policy of or interpretation by the U.S. Government. 13. Sehgal A, Grey S, Deoreo P, Whitehouse P: Prevalence, recogni-
tion, and implications of mental impairment among hemodialysis
patients. Am J Kidney Dis 30:41–49, 1997Reprint requests to Catherine Stehman-Breen, M.D., Puget Sound
Health Care System, 1660 South Columbian Way, Mailstop 111A, 14. Holley J, Schmidt R, Bender F, Dumler F, Schiff M: Gyneco-
logic and reproductive issues in women on dialysis. Am J KidneySeattle, Washington 98108, USA.
E-mail: cos@u.washington.edu Dis 29:685–690, 1997
15. US Renal Data System: USRDS 1998 Annual Data Report.
Bethesda, National Institutes of Health, National Institute of Dia-
REFERENCES betes and Digestive and Kidney Diseases, 1998
16. McNagny S, Wenger N, Frank E: Personal use of postmenopausal1. Ettinger B, Genant H, Cann C: Long-term estrogen replacement
hormone replacement therapy by women physicians in the Unitedtherapy prevents bone loss and fractures. N Engl J Med 102:319–
States. Ann Intern Med 127:1093–1096, 1997324, 1985
17. Hemminki E, Brambilla D, McKinlay S, Posner J: Use of estro-2. Hovik P, Sundsbak H, Gasemyr M, Sandvik L: Comparison of
gens among middle-aged Massachusetts Women. Ann Pharma-continuous and sequential oestrogen-progesterone treatment in
cother 25:418–423, 1991women with climacteric symptoms. Maturitas 11:75–82, 1989
18. Barret-Connor E: Lower endogenous androgen levels and dyslipi-3. Naessen T, Persson I, Adami H: Hormone replacement therapy
demia in men with non-insulin dependent diabetes mellitus. Annand the risk of first hip fracture: A prospective, population-based
Intern Med 117:807–811, 1992cohort study. Ann Intern Med 113:95–103, 1990 19. Handa V, Landerman R, Hanlon J, Harris T, Cohen H: Do4. Yaffe K, Sawaya G, Lieberburg I, Grady D: Estrogen therapy older women use estrogen replacement? Data from the Duke es-
in postmenopausal women: Effects on cognitive function and de- tablished-populations for epidemiologic studies of the elderly
mentia. JAMA 279:688–695, 1998 (EPESE). J Am Geriatr Soc 44:1–6, 1996
5. Writing group for the PEPI Trial: Effects of estrogen or estro- 20. Cauley J, Seeley D, Ensrud K, Ettinger B, Black D, Cummings
gen/progestin regimes on heart disease risk factors in postmeno- S: Estrogen replacement therapy and fractures in older women:
pausal women: The Postmenopausal Estrogen/Progestin Interven- Study of Osteoporotic Fractures Research Group. Ann Intern Med
tions (PEPI) Trial. JAMA 273:199–208, 1995 122:9–16, 1995
6. Grady D, Rubin S, Petitti D, Fox C, Black D, Ettinger B, 21. Harris R, Laws A, Reddy V, King A, Haskell W: Are women
Ernster V, Cummings S: Hormone therapy to prevent disease and using postmenopausal estrogens? A community survey. Am J Pub-
prolong life in postmenopausal women. Ann Intern Med 117:1016– lic Health 80:1266–1268, 1990
1037, 1992 22. Ferguson K, Hoegh C, Johnson S: Estrogen replacement therapy:
7. Stamper M, Colditz G: Estrogen replacement therapy and coro- A survey of women’s knowledge and attitudes. Arch Intern Med
nary heart disease: A quantitative assessment of the epidemiologic 149:133–136, 1989
evidence. Prev Med 20:47–63, 1991 23. Salamone L, Pressman A, Seeley D, Cauley J: Estrogen replace-
8. Wysowski D, Golden L, Burke L: Use of menopausal estrogens ment therapy: A survey of older women’s attitude. Arch Intern
and medroxyprogesterone in the United States, 1982–1992. Obstet Med 156:1293–1297, 1996
Gynecol 85:6–10, 1995 24. McNagy S, Jacobson T: Use of postmenopausal hormone replace-
9. Collins K, Schoen C, Joseph S, Duchon L, Simantov E, Yel- ment therapy by African American women. Arch Intern Med
lowitz M: Health Concerns Across a Woman’s Lifespan: The Com- 157:1337–1342, 1997
monweath Fund 1998 Survey of Women’s Health. New York, The 25. Couley J, Cummings S, Black D, Mascioli S, Seeley D: Preva-
Commonwealth Fund, 1999 lence and determinants of estrogen replacement therapy in elderly
10. Owen W, Madore F, Brenner B: An observational study of cardio- women. Am J Obstet Gynecol 163:1438–1444, 1990
